参考文献/References:
[1]Wu J,Xu H,Wang C,et al.The 6-year changes of epidemiology of non-alcoholic fatty liver disease among general population of northeastern in China[J].Hepatol Int,2017(11):S562.
[2]肖丽,杨玲.肠道菌群与非酒精性脂肪性肝病的关系[J].临床肝胆病杂志,2017,33(4):774-779.
[3]Blaut M.Gut microbiota and energy balance:role in obesity[J].Proc Nutr Soc,2015,74(3):227-234.
[4]Day CP,James OF.Steatohepatitis:a tale of two"hits"[J].Gastroenterology,1998,114(4):842-845.
[5]Jou J,Choi SS,Diehl AM.Mechanisms of disease progression in nonalcoholic fatty liver disease[J].Semin Liver Dis,2008,28(4):370-379.
[6]廉晓晓,郭晓霞.肠-肝轴学说的研究进展[J].中西医结合肝病杂志,2017,27(4):251-254.
[7]Paolella G,Mandato C,Pierri L,et al.Gut liver axis and probioties:their role in non-alcoholic fatty liver disease[J].World J Gastroenterol,2014,20(42):15518-15531.
[8]王全楚,步子恒.肠肝轴的现代概念及其在肝脏疾病中的作用[J].胃肠病学和肝脏病学杂志,2015,24(9):1155-1158.
[9]Ratziu V,Goodman Z,Sanyal A.Current efforts and trends in the treatment of NASH[J].J Hepatol,2015,62(1 Suppl):S65-S75.
[10]Hollister EB,Gao C,Versalovic J.Compositional and functional features of the gastrointestinal microbiome and their effects on human health[J].Gastroenterology,2014,146(6):1449-1458.
[11]Lozupone CA,Stombaugh JI,Gordon JI,et al.Diversity,stability and resilience of the human gut microbiota[J].Nature,2012,489(7415):220-230.
[12]Shen F,Zheng RD,Sun X,et al.Gut microbiota structure in patients with non-alcoholic fatty liver disease[J].Hepatol Int,2017(11):S252.
[13]Abu-Shanab A,Quigley EMM.The role of the gut microbiota in nonalcoholic fatty liver disease[J].Nature Reviews Gastroenterology and Hepatology,2010,7(12):691-701.
[14]Camp JG,Jazwa AL,Trent CM,et al.Introniccis-regulatory modules mediate tissue-Specific and microbial control of angptl4 fiaf transcription[J].PLoS geneties,2012,8(3):e1002585.
[15]Schnabl B,Brenner DA.Interactions between the intestinal microbeome and liver diseases [J].Gastroenterology,2014,146(6):1513-1524.
[16]Backhed F,Manchester JK,Semenkovich CF,et al.Mechanisms underlying the resistance to diet-induced obesity in germ-free mice[J].Proceedings of the National Academy of Sciences,2007,104(3):979-984.
[17]Nascimbeni F,Pais R,Bellen-tani S,et al.From NAFLD in clinical practice to answers from guidelines[J].J Hepatol,2013,59(4):859-871.
[18]Caricill AM,Saad MJ.The role of gut microbiota on insulin resistance[J].Nutrients,2013,5(3):829-851.
[19]Cani PD,Bibiloni R,Knauf C,et al.Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-indnced obesity and diabetes in mice[J].Diabetes,2008,57(6):1470-1481.
[20]Trauner M,Claudel T,Fickert P,et al.Bile acids as regulators of hepatic lipid and glucose metabolism[J].Dig Dis,2010,28(1):220-224.
[21]Broeders EP,Nascimento EB,Havekes B,et al.The bile acid chenodeoxycholic acid increases human brown adipose tissue activity[J].Cell Metab,2015,22(3):418-426.
[22]Fuchs C,Claudel T,Trauner M.Bile acid-nlediated control of liver triglycerides[J].Semin Liver Dis,2013,33(4):330-342.
[23]Lu W,Wang C,Luo X,et al.PB-718,a dual GLP-1 glucagon receptor agonist demonstrates superior weight loss effect and ameliorates nonalcoholic steatohepatitis(NASH)in animal models[J].Hepatol Int,2017(11):S958.
[24]Degirolamo C,Modica S,Vacca M,et al.Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor- null mice by intestinal- specific farnesoid X receptor reactivation[J].Hepatology,2015,61(1):161-170.
[25]Sayin S,Wahlstrom A,Felin J,et al.Gutmicrobiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholicacid,a naturally occurring FXR antagonist[J].Cell Metab,2013,17(2):225-235.
[26]Koeth RA.Intestinalmicrobiota metabolism of L-carnitine,a nutrient in red meat,promotes atherosclerosis[J].Nat Med,2013(19):576-585.
[27]Gao X,Liu X,Xu J,et al.Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet[J].J Biosci Bioeng,2014,118(4):476-481.
[28]Fennema D,Philips IR,Shephard EA.Trimethylamine and Trimethylamine N-Oxide,a Flavin-Containing Monooxygenase 3(FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease[J].Drug Metab Dispos,2016,44(11):1839-1850.
[29]ThuyS,LadurnerR,Volynets V,et al.Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor lconcentrations and with fructose intake[J].The Journal of nutrition,2008,138(8):1452-1455.
[30]Miele L,Valenza V,La Torre G,et al.Increased intestinal pemaeability and tight junction alterations in nonalcoholic fatty liver disease[J].Hepatology,2009,49(61):1877-1887.
[31]Henao-Mejia J,Elinav E,Jin C,et al.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J].Nature,2012,482(7384):179-185.
[32]Rivera CA,Adegboyega P,van Rooijen N,et al.Toll-like receptor-4 signaling and Kupffer cell splay pivotal roles in the pathogenesis of non-alcoholic steatohepatitis[J].J Hepatol,2007,47(2):571-579.
[33]Charlton MR,Bums JM,Pedersen RA,et al.Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States[J].Gastroemerology,2011,141(4):1249-1253.
[34]何崇信,徐正婕.内生性乙醇与非酒精性脂肪性肝病研究进展[J].实用肝脏病杂志,2016,19(1):109-112.
[35]Baker SS,Baker RD,Liu W,et al.Role of alcohol metabolism innon-alcoholic steatohepatitis[J].PLoS One,2010,5(3):e9570.
[36]Kwon HJ,Won YS,Park O,et al.Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice[J].Hepatology,2014,60(1):146-157.
相似文献/References:
[1]龙 颖,李运泽,汤中敏,等.非酒精性脂肪性肝病与血尿酸水平测定及其临床意义[J].医学信息,2018,31(07):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
LONG Ying,LI Yun-ze,TANG Zhong-min,et al.Determination of Serum Uric Acid Level and its Clinical Significance in Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(12):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
[2]崔姗姗,刘 英,江 霞.非酒精性脂肪性肝病与胰岛素抵抗的研究进展[J].医学信息,2022,35(10):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
CUI Shan-shan,LIU Ying,JIANG Xia.Research Progress on Non-alcoholic Fatty Liver Disease and Insulin Resistance[J].Journal of Medical Information,2022,35(12):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
[3]向姣姣,李国娟,杨通艳,等.肠道菌群与肥胖发病机制的研究[J].医学信息,2022,35(10):70.[doi:10.3969/j.issn.1006-1959.2022.10.017]
XIANG Jiao-jiao,LI Guo-juan,YANG Tong-yan,et al.Study on Intestinal Flora and Pathogenesis of Obesity[J].Journal of Medical Information,2022,35(12):70.[doi:10.3969/j.issn.1006-1959.2022.10.017]
[4]张 慧,胡广越,殷 红.菌群干预与免疫治疗的研究进展[J].医学信息,2022,35(11):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
ZHAHG Hui,HU Guang-yue,YIN Hong.Research Progress in Microbial Intervention and Immunotherapy[J].Journal of Medical Information,2022,35(12):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
[5]郑 颖,孙华胜,毛乾国.中医防治非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
ZHENG Ying,SUN Hua-sheng,MAO Qian-guo.Progress in Prevention and Treatment of Nonalcoholic Fatty Liver Disease by TCM[J].Journal of Medical Information,2018,31(12):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
[6]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of
Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(12):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
[7]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Journal of Medical Information,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
[8]黄玲玉,孙 东,蒋本君,等.天津市某区域体检人群非酒精性脂肪肝调查分析[J].医学信息,2019,32(04):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
HUANG Ling-yu,SUN Dong,JIANG Ben-jun,et al.Investigation and Analysis of Non-alcoholic Fatty Liver Disease in Medical Examination Population in
A Certain Area of Tianjin[J].Journal of Medical Information,2019,32(12):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
[9]余 辉,李 岳,郭宝娜.非酒精性脂肪性肝病的治疗研究[J].医学信息,2019,32(14):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
YU Hui,LI Yue,GUO Bao-na.Treatment of Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(12):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
[10]王佳欣,毛乾国.慢性乙型肝炎合并非酒精性脂肪性肝病
中医辨治的研究进展[J].医学信息,2019,32(16):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
WANG Jia-xin,MAO Qian-guo.Advances in Research on TCM Syndrome Differentiation of Chronic Hepatitis B with
Nonalcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(12):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]